ストックスクリーナーアプリを入手
9.58
4.36%
0.40
アフターアワーズ：
9.72
0.14
+1.46%
前日終値:
$9.18
開ける：
$9.13
24時間の取引高:
966.85K
Relative Volume:
0.73
時価総額：
$775.03M
収益：
$204.89M
当期純損益:
$-157.30M
株価収益率:
-4.5379
EPS:
-2.1111
ネットキャッシュフロー:
$-97.76M
1週間 パフォーマンス:
+12.05%
1か月 パフォーマンス:
-13.19%
6か月 パフォーマンス:
-20.30%
1年 パフォーマンス:
-8.50%
1日の値動き範囲:
$9.075
$9.59
1週間の範囲:
$8.405
$9.59
52週間の値動き範囲:
$8.21
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
名前
Phathom Pharmaceuticals Inc
セクター
電話
(877) 742-8466
住所
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
9.58 | 741.86M | 204.89M | -157.30M | -97.76M | -2.1111 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-27 | アップグレード | Barclays | Equal Weight → Overweight |
| 2025-12-12 | 開始されました | Raymond James | Strong Buy |
| 2025-12-09 | 開始されました | Barclays | Equal Weight |
| 2025-02-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-03 | 開始されました | Stifel | Buy |
| 2024-01-05 | 繰り返されました | Needham | Buy |
| 2023-08-09 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-03-13 | 開始されました | Craig Hallum | Buy |
| 2022-10-21 | 開始されました | Jefferies | Buy |
| 2022-05-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2021-05-12 | アップグレード | Goldman | Sell → Neutral |
| 2021-02-17 | 開始されました | BMO Capital Markets | Outperform |
| 2021-02-02 | 開始されました | Guggenheim | Buy |
| 2020-06-26 | ダウングレード | Goldman | Neutral → Sell |
| 2019-11-20 | 開始されました | Evercore ISI | Outperform |
| 2019-11-19 | 開始されました | Goldman | Neutral |
| 2019-11-19 | 開始されました | Jefferies | Buy |
| 2019-11-19 | 開始されました | Needham | Buy |
すべてを表示
Phathom Pharmaceuticals Inc (PHAT) 最新ニュース
Phathom Pharmaceuticals, Inc. (PHAT) Investigation: Bronstein, Ge - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Shareholders to Connect - ACCESS Newswire
Hennion & Walsh Asset Management Inc. Has $3.55 Million Stake in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuti - The National Law Review
Renaissance Technologies LLC Acquires New Holdings in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuticals, Inc. (PHAT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
GYRE Stock Price and Chart — NASDAQ:GYRE - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuticals, Inc. (PHAT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Investors to Reach Out - ACCESS Newswire
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 5.5%Here's Why - MarketBeat
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT) - Business Wire
Weekly Recap: Q2 revenue surge and Investigation into NASDAQ:PHAT guidance claim - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Stockholders to Reach Out - ACCESS Newswire
925,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Perceptive Advisors LLC - MarketBeat
Phathom Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PHAT) 2026-08-01 - Seeking Alpha
PHAT Reiterated by HC Wainwright & Co. -- Price Target Maintained at $26 - GuruFocus
PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals - Morningstar
Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Announces Target Price $20 - Moomoo
Raymond James Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $21 - Moomoo
H.C. Wainwright reiterates Phathom stock rating on strong revenue growth By Investing.com - Investing.com Canada
Phathom Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Phathom Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
Guggenheim cuts Phathom Pharmaceuticals price target on guidance reduction By Investing.com - Investing.com Canada
Earnings call transcript: Phathom posts Q2 2026 revenue beat, shares fall premarket - Investing.com Canada
Phathom Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Phathom Q2 Revenue Jumps 88% to $74.3 Million - Quiver Quantitative
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - globenewswire.com
Phathom Pharmaceuticals Q2 Results: Sales surge 88% YoY - scanx.trade
BlackRock (PHAT) discloses 4.38M-share passive stake in Pharmaceuticals Inc - Stock Titan
Phathom Pharmaceuticals Inc (PHAT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PHAT|Phathom Pharmaceuticals Inc|Price:11.950|Chg%:+0.510 - TradingKey
Phathom Pharmaceuticals Inc - TradingKey
Phathom Pharmaceuticals Inc (PHAT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SummitTX Capital L.P. Purchases 478,065 Shares of Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals Inc (PHAT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Phathom Pharmaceuticals Inc (PHAT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Phathom Pharmaceuticals Inc (PHAT) Institutional Confidence - TradingKey
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Phathom Pharmaceuticals (PHAT) to Post Earnings on Thursday - MarketBeat
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), Phathom Pharmaceuticals (PHAT) and Incyte (INCY) - The Globe and Mail
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Guggenheim Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $25 - Moomoo
PHAT Stock Price, Quote & Chart - ChartMill
Millennium group discloses 4.2% Phathom (PHAT) stake in amended ownership filing - Stock Titan
Avoiding Lag: Real-Time Signals in (PHAT) Movement - Stock Traders Daily
Phathom Pharmaceuticals Inc (PHAT) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):